Home Sectors Healthcare Present Valuation: Integra LifeSciences Corporation (NASDAQ: IART)

Present Valuation: Integra LifeSciences Corporation (NASDAQ: IART)

SHARE

Integra LifeSciences Corporation trades as part of the healthcare sector and trades as part of the medical devices industry. The company CEO is Peter J. Arduini. Integra Lifesciences Corp is engaged in development, manufacturing, and marketing of product lines from its technology for applications ranging from burn and deep tissue wounds to repair of dura mater in the brain to repair of nerve and tendon.

Previous Intraday Trading Performance:

The IART stock showed a previous change of 2.95% with an open at 46.96 and a close of 47.82. It reached an intraday high of 47.85 and a low of 46.62.

SeekingAlpha:  So-Young International: A Great Opportunity To Buy

Liquidity:

The stock has a market cap of $4.1b with 85.5m shares outstanding, of which the float is 83.0m shares. Trading volume reached 269,477 shares compared to its average volume of 450,790 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Integra LifeSciences Corporation shares returned 1.40% and in the past 30 trading days it returned -9.81%. Over three months, it changed -14.65%. In one year it has changed -23.55% and within that year its 52-week high was 67.50 and its 52-week low was 42.14. IART stock is 13.48% above its 52 Week Low.

Our calculations show a 200 day moving average of 54.07 and a 50 day moving average of 51.80. Currently IART stock is trading -11.55% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  So-Young International: A Great Opportunity To Buy

Earnings:

The last annual fiscal EPS for the company was reported at 0.72 that ended on 31st of December 2018, which according to the previous close, that is a PE of 66.42. Based on 8 analyst estimates, the consensus EPS for the next quarter is 0.61. The TTM EPS is 2.42, which comes to a TTM PE of 19.76.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 04/24/2019): 0.38
4thQtr of 2018 (Reported on 02/21/2019): 0.29
3rdQtr of 2018 (Reported on 10/31/2018): 0.15
2ndQtr of 2018 (Reported on 07/25/2018): 0.14
1stQtr of 2018 (Reported on 04/25/2018): 0.14

Base on our calculations, the intrinsic value per share is 68.89, which means it is possibly undervalued and has a margin of safety of 30.59%.

Indicators to Watch:

The current calculated beta is 0.95.

SeekingAlpha:  Tech Data EPS beats by $0.07, misses on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 7.16%, return on assets is 2.68%, profit margin is 5.66%, price-to-sales is 2.69 and price-to-book is 2.84.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 1  :Past Performance Score
 2  :Financial Strength Score
 3  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.